DBV TECHNOLOGIE/S (NASDAQ:DBVT) saw an uptick in trading volume on Friday . 731,600 shares changed hands during trading, an increase of 158% from the previous session’s volume of 283,971 shares.The stock last traded at $10.25 and had previously closed at $9.59.
A number of brokerages have recently commented on DBVT. Goldman Sachs Group began coverage on DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They set a “buy” rating and a $14.00 price target on the stock. ValuEngine raised DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. BidaskClub raised DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Thursday, August 15th. Finally, Zacks Investment Research cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. DBV TECHNOLOGIE/S currently has an average rating of “Hold” and an average price target of $14.81.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. The company has a market capitalization of $594.76 million, a P/E ratio of -3.02 and a beta of 1.81. The business has a 50 day moving average of $9.39 and a 200-day moving average of $9.04.
About DBV TECHNOLOGIE/S (NASDAQ:DBVT)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: How interest rates affect municipal bond prices
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.